复牌！002166，拟易主

Core Viewpoint - Rhine Biotech plans to change its controlling shareholder to Guangzhou Defu Nutrition, with the resumption of trading on December 24, following a suspension since December 10 [2][5]. Shareholder Changes - On December 22, Rhine Biotech's current controlling shareholder Qin Benjun signed several agreements with Guangzhou Defu Nutrition, including a control change framework agreement and a share transfer agreement [8]. - Qin Benjun will transfer 8.09% of his shares to Guangzhou Defu Nutrition, relinquish 25.50% of his shares, and retain voting rights for 3% of his shares. The total transaction price is 646 million yuan, with a transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9 [8][9]. New Shareholding Structure - After the transaction, Qin Benjun will hold 28.50% of Rhine Biotech's shares and 4.14% of the voting rights, while Guangzhou Defu Nutrition will hold 8.09% of the shares and 11.17% of the voting rights [9]. Strategic Focus - Guangzhou Defu Nutrition, established on December 2, 2025, is controlled by Hou Ming and Li Zhenfu, and aims to leverage its resources in the healthcare sector to enhance Rhine Biotech's operational efficiency and governance structure [10]. Acquisition Plans - Rhine Biotech intends to expand its industry chain through acquisitions, specifically by issuing shares to purchase 80% of Beijing Jinkangpu Food Technology Co., Ltd. from Defu Jinkangpu and Xiamen Defu Jinkangpu [12]. - This acquisition will allow Rhine Biotech to extend its operations into the field of nutritional enhancers, creating a closed-loop industry chain from raw materials to formulation solutions [12]. Financial Overview of Beijing Jinkangpu - As of September 30, 2025, Beijing Jinkangpu reported total assets of 593 million yuan and net assets of 535 million yuan, with net profits of 70.27 million yuan and 40.33 million yuan for 2024 and the first three quarters of 2025, respectively [13][14]. Financial Overview of Rhine Biotech - As of September 30, 2025, Rhine Biotech's total assets were 4.985 billion yuan, and net assets were 3.162 billion yuan, with net profits of 16.3 million yuan and 70.40 million yuan for 2024 and the first three quarters of 2025, respectively [15].